Last reviewed · How we verify

BP102, paclitaxel, carboplatin — Competitive Intelligence Brief

BP102, paclitaxel, carboplatin (BP102, paclitaxel, carboplatin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (taxane + platinum agent). Area: Oncology.

phase 3 Chemotherapy combination (taxane + platinum agent) Microtubules (paclitaxel); DNA (carboplatin) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

BP102, paclitaxel, carboplatin (BP102, paclitaxel, carboplatin) — Jiangsu HengRui Medicine Co., Ltd.. BP102 is a nanoparticle albumin-bound paclitaxel combined with carboplatin chemotherapy that disrupts microtubule dynamics and induces DNA crosslinking to kill cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BP102, paclitaxel, carboplatin TARGET BP102, paclitaxel, carboplatin Jiangsu HengRui Medicine Co., Ltd. phase 3 Chemotherapy combination (taxane + platinum agent) Microtubules (paclitaxel); DNA (carboplatin)
Paclitaxel, Carboplatin Paclitaxel, Carboplatin Queensland Centre for Gynaecological Cancer marketed Chemotherapy combination (taxane + platinum agent) Microtubules (paclitaxel); DNA (carboplatin)
docetaxel and cisplatin docetaxel and cisplatin Sanofi marketed Chemotherapy combination (taxane + platinum agent) Microtubules (docetaxel); DNA (cisplatin)
nab-paclitaxel，Cisplatin nab-paclitaxel，Cisplatin Yang Jianjun, PhD marketed Chemotherapy combination (taxane + platinum agent) Microtubules (paclitaxel); DNA (cisplatin)
Paclitaxel + Carboplatine Paclitaxel + Carboplatine Intergroupe Francophone de Cancerologie Thoracique phase 3 Chemotherapy combination (taxane + platinum agent) β-tubulin (paclitaxel); DNA (carboplatin)
Docetaxel, Cisplatin Docetaxel, Cisplatin Samsung Medical Center phase 3 Chemotherapy combination (taxane + platinum agent) Beta-tubulin (docetaxel); DNA (cisplatin)
Four-Weekly TC Consolidation Chemotherapy Four-Weekly TC Consolidation Chemotherapy Jiangsu Cancer Institute & Hospital phase 3 Chemotherapy combination (taxane + platinum agent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (taxane + platinum agent) class)

  1. AstraZeneca · 1 drug in this class
  2. Chinese Academy of Medical Sciences · 1 drug in this class
  3. Intergroupe Francophone de Cancerologie Thoracique · 1 drug in this class
  4. Jiangsu Cancer Institute & Hospital · 1 drug in this class
  5. Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
  6. Queensland Centre for Gynaecological Cancer · 1 drug in this class
  7. Samsung Medical Center · 1 drug in this class
  8. Sanofi · 1 drug in this class
  9. Spanish Lung Cancer Group · 1 drug in this class
  10. Yang Jianjun, PhD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BP102, paclitaxel, carboplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/bp102-paclitaxel-carboplatin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: